[go: up one dir, main page]

WO1993019741A1 - Formulation pharmaceutique - Google Patents

Formulation pharmaceutique Download PDF

Info

Publication number
WO1993019741A1
WO1993019741A1 PCT/DK1993/000117 DK9300117W WO9319741A1 WO 1993019741 A1 WO1993019741 A1 WO 1993019741A1 DK 9300117 W DK9300117 W DK 9300117W WO 9319741 A1 WO9319741 A1 WO 9319741A1
Authority
WO
WIPO (PCT)
Prior art keywords
ingestible material
active substance
material according
solid ingestible
lag
Prior art date
Application number
PCT/DK1993/000117
Other languages
English (en)
Inventor
Poul Bertelsen
Nils Gjerløv HANSEN
Kim JØRGENSEN
Original Assignee
Benzon Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benzon Pharma A/S filed Critical Benzon Pharma A/S
Publication of WO1993019741A1 publication Critical patent/WO1993019741A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)

Definitions

  • the present invention relates to a pharmaceutical formulation in the form of a coated solid ingestible material adapted to oral administration, in which the coating constitutes a barrier delaying the direct exposure of the solid material to gastrointestinal fluids; i.e. a solid substrate on which has been deposited a coating which is such that when such a coated material is swallowed by a human, it will be substantially unaffected by the pH prevailing in the stomach and in the other parts of the gastrointestinal tract, but will erode or dissolve or otherwise disintegrate within the gastrointestinal tract of the human in question, thereby first after a certain lag- time of, e.g., at least 60 minutes exposing the solid material itself to gastrointestinal fluids.
  • a certain lag- time e.g., at least 60 minutes exposing the solid material itself to gastrointestinal fluids.
  • Such formulations which may be in the form of single-unit dosage forms or multiple-unit dosage forms such as, e.g., in the form of tablets or capsules, may also be denoted, e.g., as “burst”, “pulsed”, “ ime-controlled” , “lag-time controlled” or “programmed” release pharmaceutical formulations.
  • the invention also relates to a method for preparing the ' coated solid ingestible material.
  • an aim of medicinal treatment of a particular disease or condition is to deliver the minimum required amount of a drug substance to the particular target site within the body and to avoid the presence or the accumulation of drugs at non-target sites.
  • Another aim is to maintain the necessary therapeutic concentration of the drug substance at the target site for some desirable period of time, after which the drug substance is eliminated from the body without adverse effects or formation of any toxic metabolites.
  • controlled-release drug delivery systems (sometimes also known as “sustained release”, “prolonged release”, “retard” or “mediated release” systems) have been developed mainly with the purpose of prolonging the residence time of the drug substance in the body after administration of the drug substance in form of an appropriate pharmaceutical formulation and at the same time avoiding excessively high or low levels (peak or valley levels) of the drug substance in the body.
  • An excessively high level may give rise to a drug concentration in the blood which is so high that adverse effects become apparent.
  • an excessively low concentration may lead to drug concentrations in the blood which are below the therapeutically effective level.
  • Controlled-release drug delivery systems may advantageously be used in the administration of drug substances having very short biological half-lives, or in situations where the margin between toxic and therapeutic concentration is very narrow.
  • lag-time a predetermined period of time
  • JP 63-215620 (Nippon Soda) describes a sustained release preparation having a nucleus composed of a mold which is substantially formed of water soluble high molecular substances and which contains an active substance.
  • the nucleus is provided with a coating substantially formed of the same kind of water soluble high molecular substance as in the mold.
  • water soluble high molecular substances which are capable of gelling or swelling are, e.g., hydroxypropylcellulose and hydroxypropylmethylcellulose of a relatively high viscosity.
  • the preparation is said to be capable of controlling the releasing start-up time of a sparingly water soluble drug substance and performing a zero-order functional release.
  • JP 62-246512 (Fujisawa) describes a drug preparation having repeating action comprising a rapidly dissolving part containing a principal drug; a slow- eleasing part containing a disintegrant and wax or containing a water-soluble polymeric substance; and a repeating action part containing a principal drug.
  • EP 306699 (Bayer AG) describes dihydropyridine formulations comprising a core containing a relatively sparingly water soluble dihydropyridine compound such as, e.g., nifedipine or nitrendipine, which is surrounded by a layer which slowly dissolves in an aqueous environment and thus delays the release of the dihydropyridine In the core, the formulation optionally being provided with a rapidly releasable initial dose of dihydropyridine.
  • a relatively sparingly water soluble dihydropyridine compound such as, e.g., nifedipine or nitrendipine
  • EP 338383 (Swarz Pharma AG) describes a controlled release formulation consisting of a core surrounded by several layers such as a layer comprising an active substance, a membrane layer, a layer consisting of a least one physiologically acceptable acid and a further membrane layer.
  • the present invention relates to a pharmaceutical formulation in the form of a coated solid ingestible material adapted to oral administration, wherein the coating comprises an erodable layer or a combination of erodable layers surrounding and covering the solid material and constituting a barrier delaying the direct exposure of the solid material to gastrointestinal fluids, at least one of the erodable layers containing, as a major constituent, a water soluble cellulose derivative or a mixture of water soluble cellulose deriva ⁇ tives, the viscosity of the cellulose derivative or the mixture of cellulose derivatives in the layer or layers being selected so that a test composition comprising a combination (C) of 1) a core containing an active substance in an inherently substantially freely releasable form as defined herein and 2) said erodable layer or combination of erodable layers, after a lag-time (A), defined as described herein, of at least 60 minutes during which at the most 30% by weight of the inherently substantially freely releasable active substance contained in the core is released,
  • the pharmaceutical formulation according to the invention may be produced by relatively simple and inexpensive methods such as double compression or coating-by-compression techniques (see Pharmaceutical Dosage Forms: Tablets. Vol. 1, 2nd edition, edited by Herbert A. Lieberman et al., pages 247-249).
  • the invention relates to a method for preparing a pharmaceutical formulation as defined above comprising placing a solid ingestible material optionally comprising an active substance in an inherently substantially freely releasable form and optionally at least one pharmaceutically acceptable excipient in a die which has been charged with a granulate comprising, as a major constituent, a water soluble cellulose derivative or a mixture of water soluble cellulose derivatives as defined above, adding a further quantity of the granulate so as to completely cover the solid ingestible material, and compressing the granulate around the solid ingestible material to prepare the pharmaceutical formulation.
  • the pharmaceutical formulation Upon administration the pharmaceutical formulation is capable of releasing the active substance with a certain predetermined delay, and during the lag-time there is substantially no leakage of the active substance from the core to the body environment, i.e. at the most 30% by weight of the active substance.
  • the lag-time can be varied by varying the thickness of the erodable lag-time controlling layer and/or the composition thereof, and consequently, the time for onset of the release of the active substance can be controlled.
  • the rate of release of this substance is substantially independent of the lag-time and the composition and thickness of the erodable lag-time controlling outer layer.
  • Figure 1 shows a cross-sectional view of a pharmaceutical formulation according to the invention.
  • the formulation comprises an inner core (A) containing the active substance and an erodable lag-time controlling outer layer (B) .
  • Figure 2 For the description of a dissolution or release profile the following key parameters can be determined and these parameters are used In the present context: lag-time (A) , burst-period (B) , start of burst %, and end of burst %.
  • the inflection tangent (1) can be drawn.
  • the time values at which (1) crosses the abscissa and the 100 % level are the end of the lag-time and the end of the burst- period respectively, i.e. the difference between the two values is the burst-period.
  • By drawing vertical lines through these two time values the start of burst % and the end of burst % are the two ordinates where these lines cross the dissolution or release profile.
  • Figure 3 Dissolution profile for tablets prepared as described in Example 1 herein based on the stated mean data.
  • the profile illustrates the basic system for a short lag- ime tablet, i.e. the outer layer consists of 100% Methocel® E 15.
  • Figure 4 Dissolution profile for tablets prepared as described in Example 2 herein based on the stated mean data. The profile illustrates the effect of using 15% Macrogol 6000 and 85% Methocel® E 15.
  • Figure 5 Dissolution profile for tablets prepared as described in Example 3A+B herein based on the stated mean data. The profile illustrates the effect of using 25% Macrogol 6000 and 75% Methocel® E 15.
  • Figure 6 Dissolution profile for tablets prepared as described in Example 4 herein based on the stated mean data. The profile illustrates the effect of using 25% Avicel® and 75% Methocel® E 15.
  • Figure 7 Dissolution profile for tablets prepared as described in Example 5 herein based on the stated mean data. The profile illustrates the effect of using 25% lactose and 75% Methocel® E 15.
  • Figure 8 Dissolution profile for tablets prepared as described in Example 6 herein based on the stated mean data.
  • the profile illustrates the basic system for a long lag-time tablet, i.e. the outer layer consists of 100% Methocel® E 50.
  • Figure 9 Dissolution profile for tablets prepared as described in Example 7 herein based on the stated mean data. The profile illustrates the effect of using double coating when preparing a long lag-time tablet.
  • Figure 10 Dissolution profile for tablets prepared as described in Example 8 herein based on the stated mean data. The profile illustrates the effect of using double coating with a combination of 85% Methocel® E 15 and 15% Macrogol 6000 in the first coating when preparing a long lag- ime tablet.
  • Figure 11 shows the levels of lag-time obtained for the tablets prepared in Examples 1-8 and 12 and 13 described herein (95% confidence intervals for factor means) .
  • the numbers at the abscissa refer to the Example numbers, whereas the numbers at the ordinate indicate the lag-time measured in minutes.
  • Figure 12 shows the ⁇ a ⁇ distribution observed In the in vivo study of Example 9 described herein for formulation A (short " ⁇ a ⁇ -) , B (long ⁇ ag ) and C (salbutamol) .
  • Figure 13 shows the onset of adverse drug reactions observed in the in vivo study of Example 9 herein.
  • Formulation A, B and C are defined as in Figure 12.
  • Figure 14 Dissolution profile for tablets prepared as described In Example 12 herein based on the stated mean data.
  • the profile Illustrates the effect of using double coating with 100% Methocel® E 15 in the first coating and 100% Methocel® K 100 in the second coating.
  • Figure 15 Dissolution profile for tablets prepared as described in Example 13 herein based on the stated mean data. The profile illustrates the effect of using caffeine as the active substance in the inner core and an outer layer containing 75% Methocel® E 15 and 25% Macrogol 6000.
  • Figure 16 Dissolution profile for tablets prepared as described in Example 19 herein based on the stated mean data.
  • the profile illustrates the effect of using caffeine as the active substance in the inner core and an outer layer comprising 42.4% Klucel® MF and 12.4% Klucel® LF.
  • the diameter of the tablets is 10 mm.
  • Figure 17 Dissolution profile for tablets prepared as described in Example 20.
  • the profile illustrates the effect of using caffeine as the active substance in the inner core and an outer layer comprising 42.4% Klucel® MF and 12.4% Klucel® LF, but in amounts which is greater "than the amounts used in Example 19.
  • the diameter of the tablets is 10 mm.
  • Figure 18 Dissolution profile for tablets prepared as described in Example 21. The profile illustrates the effect of using caffeine as the active substance in the inner core and an outer layer comprising 42.4% Klucel® MF and 12.4% Klucel® LF. The diameter of the tablets is 12 mm. DESCRIPTION OF THE INVENTION
  • a solid material comprising the active substance should become exposed to an aqueous environment (such as, e.g., gastrointestinal fluids) and in those cases where the active substance is present in a freely releasable form, the active substance should be released substantially instantly, and
  • the formulation principle should be applicable to a vide variety of active substances such as, e.g., freely water soluble active substances, as well as active substances which have a poorer water solubility.
  • time-controlled release is intended to mean release of the active substance at a predetermined point in time, e.g., the release of the active substance is substantially delayed until this predetermined point In time is reached.
  • controlled release is used in a broad sense to designate release of the active substance at a desired rate during a predetermined period of time.
  • the present invention meets the above-mentioned needs by providing a novel pharmaceutical formulation in the form of a coated solid ingestible material adapted to oral administration which provides the desired release profiles by proper selection of the composition of the coating and the solid material, respectively. Furthermore, one of the major drawbacks of the hitherto known formulations has been overcome or at least substantially overcome in that in a formulation according to the present invention it is also possible to incorporate a solid ingestible material comprising a freely water soluble active substance and at the same time substantially avoiding leakage of the active substance during the lag-time period.
  • novel pharmaceutical formulation of the invention is useful for medicinal treatment of a number of diseases or conditions for which it is an advantage that the therapeutic effect of the active substance is not exerted immediately after administration of the pharmaceutical formulation, i.e. diseases for which a certain delay in onset of the therapeutic effect is desirable, or in cases where daily variations in the bodily response to the active substance or in the severity of the disease symptoms are to be taken into account.
  • a pharmaceutical formulation of the invention can be used to achieve three different purposes?
  • a pharmaceutical formulation directed toward this aspect is formulated in such a way that a predetermined delay in the onset of the therapeutic effect is achieved by delaying the release of the active sub- stance from the pharmaceutical formulation in a controllable manner;
  • a pharmaceutical formulation directed toward this aspect is formulated in such a way that the release of the active substance after, e.g., oral administration is delayed independent of pH until the pharmaceutical dosage unit is delivered to the target site, e.g. to a diseased localized site in the gastrointestinal tract;
  • a pharmaceutical dosage unit directed toward this aspect is formulated in such a way that the release of the active substance is delayed independent of pH until the pharmaceutical dosage unit is delivered to the site, e.g. in the gastroin ⁇ testinal tract, where the absorbed fraction is maximal.
  • formulations according to the invention have demonstrated a remarkable capability of retaining the active substance completely during the lag-time, furthermore ensuring lag- times which are substantially independent of pH and a high degree of reproducibility of lag-times, and last but not least ensuring a rapid, instant release of the active substance when the lag-time has ended, provided that such a latter release pattern is desirable.
  • the present invention relates to a pharmaceutical formulation in the form of a coated solid ingestible material adapted to oral administration, wherein the coating comprises an erodable layer or a combination of erodable layers surrounding and covering the solid material and constituting a barrier delaying the direct exposure of the solid material to gastrointestinal fluids, at least one of the erodable layers containing, as a major constituent, a water soluble cellulose derivative or a mixture of water soluble cellulose deriva ⁇ tives, the viscosity of the cellulose derivative or the mixture of cellulose derivatives in the layer or layers being selected so that a test composition comprising a combination (C) of 1) a core containing an active substance in an inherently substantially freely releasable form as defined herein and 2) said erodable layer or combination of erodable layers, after a lag-time (A), defined as described herein, of at least 60 minutes during which at the most 30% by weight of the inherently substantially freely releasable active substance contained in the core is released
  • the percentages given In connection with the release of active substance are to be calculated on the basis of the contents of active substance prior to exposure to the aqueous body environment.
  • the requirements for the coating according to the invention are expressed as specific limits for parameters which can be calculated on the basis of an in vitro dissolution test carried out on a test composition, wherein the coating has been deposited on the outermost layer of a core, and wherein the core contains an active substance in an inherently substantially freely releasable form. It is appreciated than when a coating fulfills these requirements (see above) , in principle all types of solid ingestible materials which are adapted for oral administration may be coated with such a coating; solid materials may, e.g., be instant release formulations, controlled-release formulations or another time-controlled release formulation (see below) .
  • test composition also denoted "test composition”, “combination (C)" or “test core”
  • test core is then tested in accordance with the dissolution test described in Ph. Eur. , cf. above.
  • suitable test cores are given in the Examples 1-13 and 19-21 herein.
  • any pharmaceutical formulation which is capable of being provided with a coating and which contains an active substance in an inherently substantially freely releasable form, as defined below, may be employed as test core in the test for determining whether a specific coating fulfills the requirements and, accordingly, is a coating which is useful in accordance with the present invention.
  • the term "inherently substantially freely releasable" is used in the present context to designate an active substance in a form which preferably is water-soluble and which - when incorporated in the form of a plain formulation such as a formulation in the form of, e.g., a core - releases at least 70%, preferably at least 80%, more preferably at least 90% by weight of the active substance contained in the plain formulation within a burst-period (B) , defined as described herein (see below), of at the most 45 minutes, the release being measured as mean data determined by dissolution testing in purified water at 37 C C and in 0.1 N hydrochloric acid at 37°C in accordance with Ph.Eur. V.5.4.
  • inherently substantially freely releasable active substances may be, e.g., active substances having a water-solubility at room temperature of at least 0.1%, preferably at least about 0.5%, most preferably at least about 1% by weight, such as, e.g., actives substances like caffeine or salbutamol.
  • actives substances like caffeine or salbutamol.
  • Such active substances may be incorporated In plain formulations comprising normal excipients such as those described below.
  • a dissolution profile for a pharmaceutical formulation or composition can be drawn (see Figure 2 herein).
  • six units e.g. tablets or capsules
  • the following key parameters can be determined: lag-time (A), burst-period (B) , start of burst %, and end of burst %.
  • the inflection tangent (1) can be drawn.
  • the time values at which (1) crosses the abscissa and the 100 % level are the end of the lag-time and the end of the burst-period, respectively, i.e. the difference between the two values is the burst-period (B) .
  • B the burst-period
  • lag-time (A) is at least 60 minutes
  • start of burst % is at the most 30% by weight
  • the difference between the end of burst! and the start of burst % is at least 70% by weight, i.e. during the burst-period at least 70% by weight of the inherently substantially freely releasable active substance is released.
  • the key parameters may vary dependant on the particular therapeutic application of the pharmaceutical formulation. Thus, the following key parameters and every possible combination thereof are also relevant in connection with a pharmaceutical formulation of the present invention:
  • a start of burst % of at the most 30% such as, e.g., at the most 25%, at the most 20%, at the most 15% or at the most 10% by weight, and
  • a difference between the end of burst% and the start of burst % of at least 70% such as, e.g., at least 80% or at least 90% by weight, i.e. during the burst-period at least 70% such as, e.g., at least 80% or at least 90% by weight of the inherently substantially freely releasable active substance is released.
  • lag-time (A) is thus, in the present context, used to designate the time elapsing between exposure of a pharmaceutical formulation of the present invention or the combination denoted (C) to an aqueous medium and the time value at which the inflection tangent crosses the abscissa.
  • this time period can easily be determined by performing in vitro studies essentially as described in the Examples herein.
  • burst refers to substantially instant release of an active substance, i.e. release of at least 70% by weight of the active substance within a burst-period (B) of the most 45 minutes.
  • a relatively short burst-period like the one of at least 45 minutes as mentioned above is of course only relevant for those pharmaceutical formulations according to the invention Ln which a delayed but instant release of the active substance is desired in order to rapidly obtain an effective therapeutic concentration in the circulatory system upon administration, i.e. a relatively short burst-period is not a requirement for those pharmaceutical formulations according to the invention in which a delayed but, e.g., controlled-release of the active substance is desired.
  • the burst- period could also be termed the "burst-phase".
  • a dissolution or release profile for a pharmaceutical formulation may also be determined based on in vivo studies .
  • the lag-time T ] _ ao - is therefore defined as the time elapsing between exposure of a pharmaceutical formulation of the invention to an aqueous medium i.e. by means of the patient taking the pharmaceutical formulation of the invention and the time at which a detectable plasma concentration is measured for the first time.
  • in vivo studies can be performed essentially as described in Example 9 herein.
  • solid ingestible material is used to denote any relevant material or substance which is of established safety in connection with therapeutic treatment, which generally do not give rise to undesirable side effects in mammals, especially humans, and which has, or which is provided with, an outermost solid surface upon which the coating may be deposited.
  • the term embraces not only materials or substances which are substantially solid throughout, but also materials or substances which in themselves are fluids such as, e.g., liquids, but which have been encapsulated in or mixed with a further material so that this material represents the outermost solid surface.
  • An example of a relevant liquid material or substance which may be provided in an encapsulated form before being further provided with a coating according to the invention is, e.g., triglyceryl nitrate and nicotine.
  • solid Ingestible material is used in the present context to embrace materials which in themselves are pharmaceutical formulations (such as, e.g., instant release formulations, controlled-release formulations or time-controlled release formulations) .
  • an active substance may be present in an inherently substantially freely releasable form or in a controlled-release or time-controlled release form (as defined above) .
  • the release of the active substance may be, e.g., as an instant release, a controlled release or as a further time-controlled release; in the case of oral pharmaceutical formulations, instant release denotes a release which substantially corresponds to the release of active substances achieved using conventionally formulated plain uncoated tablets (e.g. at least 80% of the drug substance is released within 1 hour, as determined in a standardized in vitro test, e.g., as described in United States of America Pharmacopoeia, USP XXII) .
  • the solid ingestible material comprises an active substance such as, e.g., an active substance selected from the group consisting of drugs, peptides, proteins, nutrients, vitamins or mixtures thereof.
  • a pharmaceutical formulation of the invention is preferably intended for oral use and is preferable in form of a unit dosage form, such as,e.g., a tablet.
  • a unit dosage form such as,e.g., a tablet.
  • the solid ingestible material preferably also has a shape of a tablet.
  • the solid ingestible material comprises the active substance in combination with at least one pharmaceutically acceptable carrier or excipient, although there may be cases where it is advantageous that the solid ingestible material only contains the active substance.
  • the solid ingestible material (preferably comprising an active substance) may in itself be in the form of a pharmaceutical formulation such as, e.g., pellets, granules, unit dosage forms such as, e.g., tablets or capsules, or in the form of cores.
  • a pharmaceutical formulation such as, e.g., pellets, granules, unit dosage forms such as, e.g., tablets or capsules, or in the form of cores.
  • core Is used in a broad sense to embrace a solid ingestible material comprising an active substance in combination with at least one pharmaceutically excipient.
  • Suitable carriers and excipients which can be used in the preparation of such a core include:
  • fillers such as lactose, saccharose, dextrose, mannitol, sorbitol, maltodextrin, dextrin, calcium phosphate, dicalcium phosphate, tri- calcium phosphate, starch and microcrystalline cellulose;
  • binders such as gelatin, hydroxypropylcellulose, hydroxypropylmethyl- cellulose, methylcellulose, polyvinylpyrrolidone, saccharose, acacia, tragacanth, starch, sodium alginate, ammonium calcium alginate, sodium carboxymethylcellulose, ethylcellulose and polyacrylamldes;
  • disintegrants such as crospovidone, cross-linked sodium carboxyme ⁇ thylcellulose, mlcrocrystalline cellulose, sodium carboxymethyl starch, starch, alginic acid, croscarmellose sodium, guar gum, alumi ⁇ nium magnesium silicate, aluminium silicate and pregelatinized starch;
  • wetting agents and solubilizing agents such as sodium lauryl sulpha ⁇ te; magnesium lauryl sulphate; dioctyl sodium sulfosuccinate; poloxa- mers such as Pluronic; polyoxyethylene alkyl ethers such as cetoma- crogol; polyoxyethylene esters; polyoxyethylene castor oil derivatl- ves such as Polyoxyl 35 castor oil and Polyoxyl 40 hydrogenated castor oil; polyoxyethylene sorbitan fatty acid esters such as poly-" sorbates 20, 40, 60 and 80; and polyoxyethylene stearates such as polyethyleneglycol 400 monostearate, glycerol monostearate and Po ⁇ lyoxyl 40 stearate;
  • lubricants or glidants such as calciu stearate, glycerin, hydrogena ⁇ ted vegetable oil, magnesium stearate, zinc stearate, starch, dibasic calcium phosphate, magnesium carbonate, magnesium oxide, calcium silicate, silica, micronized stearate, light mineral oil, polyethyle ⁇ ne glycol, propylene glycol, talc, polyoxyethylene stearates, sodium lauryl sulphate and magnesium lauryl sulphate;
  • buffering agents such as primary, secondary or tertiary salts of phosphoric acid, salts of phthalic acid, salts of citric acid, salts of tartaric acid, and salts of amino acids such as glycine.
  • a core is prepared according to methods well known in pharmaceutical practice, and when the core is in the form of a tablet it is prepared by means of compression of the core ingredients into a tablet. Before the compression step, the core ingredients may be admixed and/or granulated such as is well known in the art.
  • the core may comprise a multiplicity of units, each unit comprising an active substance optionally together with at least one pharmaceutically acceptable excipient and, optionally, being provided with a controlled-release coating. After administration and erosion of the lag-time controlling outer layer the core disintegrates into a multiplicity of units.
  • a core it is possible to obtain a controlled-release of the active substance or it is possible to incorporate different kinds of active substances in the units.
  • units with different coatings or different thicknesses of the coating to provide the desired release pattern of the active substance.
  • units with coatings as well as uncoated units are incorporated in the core of the dosage unit of the invention.
  • the core itself is uncoated (it should, however, be understood that the resulting pharmaceutical formulation of course is coated with a coating of the invention) and the active substance is in an inherently substantially freely releasable form which is released upon contact of the core with the aqueous medium.
  • a coating of the invention when applied on the test core also are fulfilled in those pharmaceutical formulations in which an active substance in an inherently substantially freely releasable form is comprised in the solid ingestible material such as, e.g., in a core.
  • One important embodiment of the present invention is a pharmaceutical formulation in which the pattern of release of the active substance from the formulation after a predetermined lag-time corresponds essentially to the pattern of release of the active substance from the core before being provided with the coating.
  • the coating has the function of limiting the diffusion of active substance but it does not substantially influence the pattern of release of the active substance when the release starts after substantial dissolution or erosion of the coating.
  • the lag-time should not be too long.
  • the lag-time plus the time for release of the drug substance should obviously not exceed the gastrointestinal transit time of the formulation.
  • an erodable layer or a combination of erodable layers is used in the present context to designate the coating of a solid ingestible material, i.e. an outer layer which surrounds and covers the solid ingestible material of the formulation, and constitutes a barrier delaying the direct exposure of the solid ingestible material to gastrointestinal fluids.
  • At least one of the erodable layers contain, as a major constituent, a water soluble cellulose derivative or a mixture of water soluble cellulose derivatives which have such a viscosity that the above-mentioned requirements for the coating are fulfilled when testing a relevant test combination (C) (see above) .
  • the lag-time (A) can be varied.
  • a shorter lag-time can inter alia be obtained by using a smaller amount of water soluble cellulose derivative or mixture of water soluble cellulose derivatives in the erodable layer or by using a water soluble cellulose derivative or mixture of water soluble cellulose derivatives with a lower viscosity, and, correspondingly, at longer lag time can be obtained using a larger amount of water soluble cellulose derivative or mixture of cellulose derivatives, or by using a water soluble cellulose derivative or mixture of water soluble cellulose derivatives of higher viscosity.
  • water soluble cellulose derivatives in general are accepted as coating material, see, e.g., GB 2,245,492 (Zambon Group SPA), DE 3,013,059 (Sandoz Patent GMBH), EP 411,590 (Arnold, J. D.), EP 284,514 (Norwich Easton Pharmaceuticals Inc.), GB 793,818 (Bardani, F. M.), FR 2,276,108 (Shin-Etsu Chemical Co. Ltd.), GB 2,212,396 (The Procter & Gamble Compagny) , EP 013,131 (Mundiphar a AG), EP 210,540 (Fujisawa Pharmaceutical Co. Ltd.), US 4,775,536
  • aqueous body fluid e.g. gastric fluid
  • the outermost hydrated layer then slowly dissolves or erodes. As new underlying material is exposed to aqueous body fluid it becomes hydrated, thus ensuring the persistence of an outermost hydrated layer. This process occurs continuously until the lag-time control ⁇ ling outer layer (i.e. the coating itself or an erodable layer comprised in the coating) is substantially eliminated from the formulation.
  • the lag-time control ⁇ ling outer layer i.e. the coating itself or an erodable layer comprised in the coating
  • the solid material of the pharmaceutical formulation becomes exposed to the aqueous body fluid.
  • the solid material can then disintegrate so that the active substance will become released, or, in those cases where the solid material is in the form of a non-disintegrating controlled-release matrix, the release of active substance will be initiated by the relevant release mechanism .
  • At least one of the erodable lag-time controlling layer or layers of a pharmaceutical formulation according to the invention comprises, as a major constituent, a water soluble cellulose derivative or a mixture of water soluble cellulose derivatives, which have such a viscosity that a test composition comprising a combination (C) of 1) a core containing an active substance in an inherently substantially freely releasable form as defined herein and 2) said erodable layer or combination of erodable layers, after a lag-time (A), defined as described herein, of at least 60 minutes during which at the most 30% by weight of the inherently substantially freely releasable active substance contained in the core is released, releases at least 70% by weight of the inherently substantially freely releasable active substance contained in the core within a burst-period (B) , defined as described herein, of at the most 45 minutes, the said releases being measured as mean data determined by dissolution testing in purified water at 37°C and in 0.1 N hydrochlor
  • a drug delivery system is obtained from which the release of the active substance can be controlled in such a way that the onset of release first starts after a predetermined period of time.
  • the coating constitutes a barrier delaying the direct exposure of the solid ingestible material or the active substance contained in the core to gastrointestinal fluids and limits the diffusion of water from the aqueous medium to the solid ingestible material, so that release of an active substance from the solid ingestible material takes place predominantly when the coating has been dissolved or eroded away by the aqueous medium.
  • the dissolution rate of the water soluble cellulose derivative can be determined as described in Examples 14-16 herein by measuring the concentration of hydroxypropylmethylcellulose in the dissolution medium when dissolution testing is performed on a formulation as described in Example 14 in purified water at 37°C and in 0.1 N hydrochloric acid at 37°C in accordance with Ph.Eur. V.5.4. (1991 edition) , using a dissolution apparatus equipped with baskets rotating at 100 rpm.
  • the standard viscosity of the hydroxy ⁇ propylmethylcellulose seems to vary inversely proportional to the amount of HPMC dissolved by time as the amounts of HPMC dissolved by time were 0.8 mg/minutes, 0.6 mg/minutes and 0.3 mg/minutes for the standard viscosities of 15 cP, 50 cP and 100 cP, respectively. This finding is consistent with the results of the other Examples herein that when the viscosity of the HPMC is increased (when the same amount of HPMC is used) , the lag-time is also increased.
  • the pharmaceutical formulation according to the invention may comprise at least one erodable layer (I) , in which the cellulose derivative or the mixture of water soluble cellulose derivatives has a viscosity which contributes to securing that the start of burst % is below 30%, and at least one other erodable layer (II) , in which the cellulose derivative or the mixture of water soluble cellulose derivatives has a viscosity which contributes to securing that the lag-time (A) is at least 60 minutes.
  • a longer lag-time is desirable, such as, e.g., a lag-time of at least 90 minutes, at least 2 hours, at least 3 hours or at least 5 hours.
  • such layers are also denoted:
  • the invention includes pharmaceutical formulations which comprise at least two erodable layers.
  • Such two erodable layers will normally be layers of different composition, and will often be layers both of which are of the types defined herein, but designed so that one layer is particularly designed with respect to obtaining one particular property, such as, e.g., a long lag-time, and another layer is particularly designed with respect to obtaining another property, e.g. a low start of burst %.
  • one combination according to the invention comprises two layers, the cellulose derivative or mixture of cellulose derivatives of one layer (I) having a viscosity which contributes to securing that the start of burst %, as defined herein, is below 30%, and at least one erodable layer which may either be the same layer (I) or a different layer (II) , in which the cellulose derivative has a viscosity which contributes to securing that the lag-time (A) is at least 60 minutes.
  • the start of burst %-regulating layer (I) and the lag-time regulating layer (II) are one and the same layer, which means that the cellulose derivative or mixture of cellulose derivatives of such one erodable layer is/are capable of permitting both a satisfactory lag-time, that is, a lag-time within the limitations defined above, and a satisfactory burst.
  • the inner layer that is, the layer which is normally in immediate contact with the solid ingestible material, is the one with the lower viscosity.
  • a specific embodiment of such pharmaceutical formulations is, accordingly, a formulation comprising two layers, in which the cellulose derivative of the layer (I) has a viscosity of at the most 15 centipoise and the cellulose derivative of the layer (II) has a viscosity of at the most 50 centipoise (see Example 6 herein) , and a formulation comprising two layers, in which the cellulose derivative of the layer (I) has a viscosity of at the most 15 centipoise and the cellulose derivative of the layer (II) has a viscosity of at the most 100 centipoise (see Example 12 herein) .
  • the lag-time controlling layer of the dosage unit of the present invention may advantageously hydrate substantially independent of pH in the aqueous body fluid, and the dissolution or erosion of the outer layer should preferably be substantially independent of pH.
  • the lag-time of release of an active substance can be adjusted in various ways such as those described in the following:
  • the particular choice of the ingredients present in the lag- time controlling layer is of importance, e.g. the choice of the water soluble cellulose derivative or the mixture of water soluble cel ⁇ lulose derivatives can affect the lag-time.
  • the higher the viscosity of the water soluble cellulose derivative or the mixture of water soluble cellulose derivatives the longer the lag-time (A).
  • HPMC hydroxypropylmethylcellulose
  • HPMC hydroxypropylmethylcellulose
  • Another way of regulating the lag-time is to use a polymeric substance of a different nature.
  • HPMC essentially hydrophilic polymer
  • HPC hydroxypropylcellulose
  • the thickness of the coating or lag-time regulating layer may influence the lag-time in such a way that an increase in thickness is assumed to increase the lag-time.
  • the coating has a thickness of at least about 0.1 mm, preferably in a range corresponding to the range of about 0.5-5 mm, and/or the volume percentage of the coating is at least about 15% of the volume of the total dosage unit.
  • an inner layer of, e.g., HPMC may be applied as, e.g., a "start of burst %"-regulating layer, and, e.g., HPC may be applied in an outer layer as, e.g., a "lag-time"-regulating layer.
  • Preferred cellulose derivatives or constituent of cellulose derivative mixtures are selected from the group consisting of methylcelluloses, such as, e.g., Methocel® A (methylcellulose USP) , sodium carboxymethylcelluloses, hydroxyethylcelluloses, hydroxy ⁇ propylcelluloses (HPC), such as, e.g., Klucel®, and hydroxypropylmethylcelluloses (HPMC), such as, e.g., Methocel® E, F, J and K.
  • methylcelluloses such as, e.g., Methocel® A (methylcellulose USP)
  • HPC hydroxyethylcelluloses
  • HPMC hydroxypropylmethylcelluloses
  • Preferred water soluble cellulose derivatives are HPMC's, HPC's and methylcelluloses.
  • HPMC hydroxypropylmethylcelluloses
  • HPMC's having a methoxy group content in the range of about 19-30% and/or a hydroxypropyl group content in the range of about 4-12%, such as, e.g., Methocel® E (hydroxypropylmethylcellulose, USP 2910), Methocel® F (hydroxypropylmethylcellulose, USP 2906), Methocel® J and Methocel® K (hydroxypropylmethylcellulose, USP 2208).
  • hydroxypropylcelluloses are, e.g., Klucel® J and L, and especially preferred methylcelluloses are methylcelluloses having a methoxy group content in the range of about 26-33%, such as, e.g., Methocel® A 15.
  • the cellulose derivative or the mixture of cellulose derivatives of at least one layer of the erodable lag-time controlling layer typically have a viscosity of at the most about 100 centipoise, as measured on a 2% w/w aqueous solution at 20°C, preferably in the range of about 15-50 cps.
  • Particularly preferred cellulose derivatives are hydroxypropylmethylcelluloses having a viscosity (measured as defined above) in the range of about 1-100 cps. Examples of such HPMC's are Methocel® E 5, Methocel® E 15, Methocel® E 50 and Methocel® K 100. It is believed that any desired viscosity may be obtained by carefully selecting and mixing cellulose derivatives; also cellulose derivatives having a high viscosity such as Methocel® E 4000 can form part of these mixtures.
  • the erodable coating of the invention may further comprise pharmaceu- tically acceptable carriers and/or exclpients such as those mentioned above in connection with the core, especially preferred further constituents are fillers, lubricants or glidants.
  • the coating of the invention may additionally contain a non-hydrogel forming water-soluble hydrophilic polymer, such as a glycol.
  • a non-hydrogel forming water-soluble hydrophilic polymer such as a glycol.
  • glycols are polyethylenglycoles, e.g. Macrogol® 6000.
  • Macrogol® 6000 polyethylenglycoles
  • the addition of Macrogol® 6000 have a clear positive effect on the dissolution of the active substance as the "end of burst %" increases.
  • the pharmaceutical formulation is targeted for a specific site in the intestines (either because it is desired to treat a disease localized at a specific site or because there is a narrow absorption window for the particular active substance) it may be advantageous to provide the formulation with an outer coating such as an enteric coating. Since the individual gastric transit times vary significantly, in contrast to intestinal transit time, an enteric coating will prevent contact of the dosage unit per se with an aqueous medium until the dosage unit has passed into the intestines; the active substance can then be released after a predetermined lag-time corresponding to the transport time to the particular target site.
  • an outer coating such as an enteric coating. Since the individual gastric transit times vary significantly, in contrast to intestinal transit time, an enteric coating will prevent contact of the dosage unit per se with an aqueous medium until the dosage unit has passed into the intestines; the active substance can then be released after a predetermined lag-time corresponding to the transport time to the particular target site.
  • no active substance e.g. drug
  • the coating or the erodable layer or at least one of the erodable layers contains an amount of active substance embedded therein, the active substance being released during and as a consequence of the erosion of the layer.
  • This embodiment of the invention is especially valuable when a combination of time-controlled release and burst-release is a desirable release pattern.
  • a further layer comprising active substance can be applied on the pharmaceutical formulation according to the invention in order to release the active substance from such an outermost layer substantially immediately after administration of the pharmaceutical formulation.
  • a pharmaceutical formulation of the invention comprises a coated solid ingestible material which has further been provided with a coating comprising a layer of a solid ingestible material and at least one erodable layer.
  • the solid ingestible materials contained in the pharmaceutical formulation may be the same or different materials and the same applies for the at least two coatings.
  • a pharmaceutical formulation of the present invention preferably comprises at least one active substance.
  • the active substance is preferably comprised in the solid ingestible material but may also be in the coating or in an outermost layer of the pharmaceutical formulation.
  • active substance is used in the present context to designate any physiologically or pharmacologically active substance which produces a local or systemic effect in animals, which term includes warm-blooded mammals, such as humans.
  • Preferred active substances are drugs, peptides, proteins, vitamins or nutrients.
  • all kinds of active substances may be employed in a pharmaceutical formulation of the invention.
  • the usefulness of a particular active substance is dictated by therapeutic demands and is substantially unaffected of the physico-chemical properties of the active substance Itself.
  • active substances being substantially freely water soluble may successfully be incorporated in a pharmaceutical formulation of the invention as well as active substances being less water soluble.
  • a pharmaceutical formulation of the invention is, however, especially well suited for time- controlled release of active substances which are easily soluble in an aqueous environment.
  • Variations in the pattern of time-controlled release of an active substance from a pharmaceutical formulation according to the present invention can be achieved by varying the composition of the coating, and, therefore, formulations according to the present invention can advantageously be used for a wide variety of active substances and for a wide variety of medical indications.
  • a certain lag-time will in some circumstances be of value in order to secure the patient's compliance; therefore slimming agents, tranquilizers and diuretics are examples of embodiments of the pharmaceutical formulations according to the invention wherein pharmaceutical formulations having a lag-time (A) of at least 90 minutes are considered to be useful.
  • suitable dosage units according to the invention will be pharmaceutical formulations wherein a lag-time (A) of at least 2 hours e.g. at least 3 hours is obtained.
  • a lag-time (A) of at least 2 hours e.g. at least 3 hours is obtained.
  • a pharmaceutical formulation of the invention will be advantageous since the dosage unit can be ingested at a time convenient-for the patient and the therapeutic effect will be exerted at a time when the severity of disease symptoms is maximal or the sensitivity toward side-effects is minimal.
  • a drug substance which is especially suitable for use in a pharmaceutical formulation of the present invention is a drug substance having a short to medium biological half-life and exhibiting a therapeutic effect which is well correlated with the concentration in the biophase (e.g. the concentration of the drug substance in the blood after administration) , and which becomes relatively rapidly distributed in the biophase.
  • circadian variations in the kinetic parameters for the particular drug substance must be taken into account when designing a particular pharmaceutical formulation.
  • daily variations have been reported for absorption rate, renal clearance, volume of distribution, protein binding and hepatic recirculation of drug substances.
  • the variations can be split up in pharmacodynamic variations, i.e. variations in drug sensitivity, and in pharmacokinetic variations, i.e. variations in absorption, distribution, metabolism and excretion processes.
  • the common back ⁇ ground is physiological variations in the autonomic nerve system, in the hormonal system and in CNS functions. As a consequence of these physiological variations many diseases may be presumed to show diur ⁇ nal variations in symptoms or severity.
  • Cardiovascular parameters e.g. blood pressure, heart rate, blood flow, blood volume and ECG
  • cardiovascular diseases e.g. ischemic heart diseases, acute myocardial infarction, stroke, hypertension and angina pectoris.
  • Preferred drug substances for use in a pharmaceutical formulation of the invention for the treatment of cardiovascular diseases are e.g.
  • adrenergic beta- receptor blocking agents such as, e.g., metoprolol
  • calcium antagonists such as, e.g., nifedipine
  • organic nitrates such as, e.g., sorbid nitrate, isosorbid nitrate including isosorbid mono- and dinitrate
  • diuretics such as, e.g., furosemide or combinations thereof.
  • a classical symptom in rheumatoid arthritis is morning stiffness.
  • Long-acting NSAID (non-steroid anti-inflammatory drugs) or controlled-release formulations of short-acting drug substances have previously been developed In order to maintain a constant therapeutically active concentration during the morning hours.
  • the maintenance of the concentration is believed to be at the expense of an observed increase in frequency of side effects.
  • Clinical studies have demonstrated a better therapeutic effect and a decrease in side-effects by use of a high evening dose.
  • a pharmaceutical formulation of the present invention which is formulated to obtain a time-controlled release with a high release in the late evening and a low release in the morning is believed to combine convenient dosing for the patients with an optimal plasma profile.
  • Peripherally acting analgesics with short to medium duration of therapeutic effects such as indomethacin and ibuprofen, are therefore preferred drug substances for use in a pharmaceutical formulation of the inven- tion. 3.
  • a pharmaceutical formulation of the invention may be formulated to release the active substance in the morning, and preferred drug substances for use in such a pharmaceutical formulation for the treatment of respiratory diseases, e.g. asthma and bronchitis, are xanthine derivatives, such as, e.g., theophylline; and adrenergic beta-receptor stimulating drugs, such as, e.g., salbutamol.
  • Circadian variations in connection with peptic ulcer are based on the clinical finding that a single evening dose of cimetidine is just as effective as dosage twice daily with respect to both the healing time for ulcers and the prevention of recurrence of peptic ulcers.
  • a treatment with a pharmaceutical formulation of the invention that secures a neutral stomach during the night hours and the early morning hours is therefore believed to give an effective treatment.
  • Preferred drug substances for use in a pharmaceutical formulation of the present invention for the treatment of gastrointestinal ulcers are antacids, or H2 histamine receptor blocking agents, such as, e.g., cimetidine. 5.
  • Cyclic antidepressant drugs such as, e.g., trimipramin are preferred for use in a pharmaceutical formulation of the present invention for the treatment of depression.
  • Preferred drug substances for use in a pharmaceutical formulation of the invention are, e.g., corticosteroids.
  • Preferred drug substances for use in a pharmaceutical formulation of the present invention for the treatment of cancer are, e.g., antibiotics such as, e.g., doxorubicin; alkylating agents as well as other cytostatic agent such as, e.g., cisplatin.
  • dosage units according to the invention wherein at the most 25%, such as at the most 10%, 15% or 20 % of the active substance is released during the lag-time (A) in order to ensure that the feedback system is not triggered and the medicament thus can exert maximal effect when it is released.
  • a dosage unit according to the invention can also be used with the purpose of achieving local effect in the gastrointestinal tract.
  • a preferred drug substance for this use is, e.g., 5-aminosalicylic acid.
  • a dosage unit according to the invention can be used to deliver the drug at a specific site from which the fraction absorbed into the systemic system is maximal. It is contemplated that especially under such circumstances but not limited to these it will be advantageous to use a pharmaceutical dosage unit according to the invention in which at least 70% by weight of the active substance is released within a burst-period (B) of the most 30 minutes. For some clinical conditions it might even be advantageous to use a pharmaceutical dosage unit according to the invention in which at least 80% of the active substance is released during the burst-period (B) .
  • Preferred drug substances for this use are, e.g., peptides and proteins, such as, e.g., antidiuretic hormone or calcitonin.
  • a pharmaceutical formulation of the invention may preferably be a pharmaceutical formulation unit for oral administration, comprising a combination (C) of 1) a core containing an active substance in an inherently substantially freely releasable form and 2) an erodable layer or a combination of erodable layers surrounding and covering the core and constituting a barrier delaying the direct exposure of the inherently substantially freely releasable active substance contained in the core to gastrointestinal fluids, at least one of the erodable layers containing, as a major constituent, a water soluble cellulose derivative or a mixture of water soluble cellulose derivatives, the cellulose derivative or the mixture of cellulose derivatives having a viscosity which permits that the unit, after a lag-time (A), defined as described herein, of at least 60 minutes during which at the most 30% by weight of the inherently substantially freely releasable active substance contained in the core is released, releases at least 70% by weight
  • A lag-time
  • this combination (C) may be combined with further barrier layers of the same or * different release principle and/or further or more elaborate cores containing the same or different active substances.
  • the invention relates to a pharmaceutical formulation comprising a combination (C) as defined above combined with a further combination (C) as defined above (termed C), the erodable barrier layer 2 (termed 2') of which is arranged so that it becomes exposed when the inherently substantially freely releasable active substance (1) of the first combination (C) is released, so that the pharmaceutical formulation, after a lag-time (A') of at least 60 minutes during which at the most 30% by weight of the inherently substantially freely releasable active substance is released, releases at least 70% by weight of the inherently substantially freely releasable active substance (1') contained in the further combination (C) within a burst-period (B'), defined as described herein, of at the most 45 minutes, the said releases being measured as mean data determined by dissolution testing in purified water at 37°C and in 0.1 N hydrochloric acid at 37 C C in accordance with Ph.Eur.
  • dosage units in which the combination (C) is combined with an additional amount of active substance contained -in the core, the additional amount of active substance being in a controlled release formulation. It is, however, obvious that substantially all of the active substance present in the core of a pharmaceutical formulation according to the invention should be released after a certain period of time after administration, which period together should not exceed the total time of transit of the dosage unit through the gastrointestinal tract.
  • inventions comprising an active substance in an inherently substantially freely releasable form are pharmaceutical formulations in which the erodable layer 2) or at least one of the erodable layers 2) (see above) of the combination (C) contains an amount of active substance embedded therein so that the active substance is released during and as a consequence of the erosion of the layer. Furthermore, an additional amount of active substance may be applied on a pharmaceutical formulation of the invention in order to substantially immediately releasing the active substance after administration.
  • the pharmaceutical formulation of the invention is preferably intended for oral use in the form of a dosage unit.
  • Formulations for oral use comprise tablets and capsules.
  • a preferred dosage unit for oral use is in the form of a tablet.
  • a pharmaceutical formulation according to the present invention can be in the form of a single-unit formulation or a multiple-unit formulation.
  • the coating may, e.g., be applied on the solid ingestible material by means of a coating-by-compression technique, i.e. a solid ingestible material optionally comprising an active substance and optionally at least one pharmaceutically acceptable excipient is placed in a die which has been charged with a granulate comprising, as a major constituent, a water soluble cellulose derivative or a mixture of water soluble cellulose derivatives, thereafter a further quantity of the granulate so as to completely cover the solid ingestible material is added, and the granulate Is compressed around the solid ingestible material to prepare the pharmaceutical formulation.
  • a coating-by-compression technique i.e. a solid ingestible material optionally comprising an active substance and optionally at least one pharmaceutically acceptable excipient is placed in a die which has been charged with a granulate comprising, as a major constituent, a water soluble cellulose derivative or a mixture of water soluble cellulose derivatives, thereafter a further quantity of the
  • the method for the preparation of a pharmaceutical formulation according to the present invention may comprise the following steps (in the following the method is described for a pharmaceutical formulation in which the solid ingestible material Is in the form of a core comprising an active substance) :
  • a tablet having a core and a coating (lag-time controlling outer layer) by placing the core, prepared as described in 1) centrally in a die which has been charged with a sufficient and well-defined quantity of material as described in 2) as the bottom layer.
  • a metal tube may be used having an internal diameter of the same dimension as the core and an external diameter as the die. Subsequently, an additional, well-defined quantity of material as described in 2) is added as a top layer, and a tablet is compressed.
  • the above-mentioned process can be repeated using the tablet produced under 3) as core.
  • the tablet produced as described in 3) or 4) can be provided with a coating, preferably an enteric coating, by means of methods well known in the art.
  • the dissolution profile of the core was determined by dissolution testing in purified water at 37°C and in 0.1 N hydrochloric acid at 37°C in accordance with Ph. Eur. V.5.4. (1991 edition), using a dissolution apparatus equipped with baskets rotating at 100 rpm. Determined as mean data, the core releases at least 90% by weight of the total content of salbutamol sulfate during a period of at the most 45 minutes.
  • Amylum maydis 40.0
  • Magnesium stearate Magnesium stearate manufactured by Breyer Che ie B.V.
  • Lactose A fine particular lactose manufactured by Cooperative Condensfabrik-Friesland Co. Tabletose® A direct compressible lactose manufactured by Meggle
  • the apparatus used is a USP/Ph.Eur. dissolution apparatus (Sotax AT6 or AT7) equipped with baskets.
  • the dissolution medium is thermostatically controlled at 37°C, and the rotation speed for the baskets is set at 100 rpm.
  • test is performed in purified water as well as in 0.1 N- hydrochloric acid.
  • the composition of the core is described above, and the diameter of the core was 8.0 mm.
  • An outer layer was applied on the core by means of a coating-by-compression technique. Different compositions of the coating, I.e. of the outer layer or outer layers, are used in the examples 1-9.
  • Example 1 Results The tablets prepared in Example 1 were tested and analyzed as described under "Method of Analysis", i.e. for all tablets dissolution testing was carried out in acidic as well as neutral dissolution media. The results are given below in the form of a table and in Figure 3 as dissolution profile. In Figure 11 is shown the lag-times obtained for tablets prepared according to Examples 1- 8.
  • Tablets were prepared as In Example 1 using an outer layer composi ⁇ tion as follows:
  • Macrogol 6000 was sieved (300 ⁇ m mesh screen) and then premixed with Methocel® E 15 Premium (300 ⁇ m mesh screen) . The mixture was then sieved (300 ⁇ m mesh screen) and finally mixed.
  • 150 mg (45.5%) outer layer granulate was pre-charged in a die with a punch diameter of 11.0 mm.
  • the core was placed centrally in the die by means of a centering tube. Having centered the core in the die, the die was filled with the remaining amount of the outer layer granulate (180 mg) and a round, plane tablet was produced by applying a compression pressure of approximately 10-12 kN.
  • the tablet height was approximately 4.8 mm.
  • Example 2 The tablets prepared in Example 2 were tested and analyzed as described under "Method of Analysis", i.e. for all tablets dissolution testing was carried out in acidic as well as neutral dissolution media. The results are given below in the form of a table and in Figure 4 as dissolution profile. In Figure 11 is shown the lag-times obtained for tablets prepared according to Examples 1- 8.
  • % w/w Methocel® E 15 Premium 75 Macrogol 6000 25 Macrogol 6000 was sieved (mesh screen 300 ⁇ m) and was then premixed with Methocel® E 15 Premium (mesh screen 300 ⁇ m) . The mixture was then sieved (mesh screen 300 ⁇ m) followed by final mixing.
  • Tablets were produced applying a compression pressure of approximately 15-20 kN. Tablets produced as described had an average height of approx. 4.7 mm.
  • Tablets were prepared as described in Example 3A, i.e. using outer layer composition 3.
  • Tablets were produced as described in Example 3A. Tablets were pro ⁇ quizzed by applying a pressure of approximately 11-13 kN. Tablets manufactured as described had a height of 4.8 mm.
  • Example 3A and 3B were tested and analyzed as described under "Method of Analysis", i.e. for all tablets dissolution testing was carried out in acidic as well as neutral dissolution media. The results are given below in the form of a table and in Figure 5 as dissolution profile.
  • Figure 11 is shown the lag-times obtained for tablets prepared according to Examples 1- 8. 80 tablets were produced as described in Example 3A, and 12 tablets were produced as described in Example 3B.
  • the results of the dissolution testing of the tablets prepared appear below as Table 3 including results for Example 3A (5 tablets) , Example 3B (12 tablets) , and cummulated results for Example 3A+B (17 tablets) .
  • the dissolution profile based on the stated mean data for Example 3A+B appears from Figure 5.
  • Avicel® PH 101 was sieved (300 ⁇ m mesh screen) and then premixed with Methocel® E 15 Premium (300 ⁇ m mesh screen) . The mixture was then sieved (300 ⁇ m mesh screen) and finally mixed.
  • Tablets was manufactured as described in Example 2. Tablets were produced by applying a compression pressure of approx. 20-23 kN. The tablets manufactured as described had an average height of approximately 4.5 mm.
  • Example 4 The tablets prepared in Example 4 were tested and analyzed as described under "Method of Analysis", i.e. for all tablets dissolution testing was carried out in acidic as well as neutral dissolution media. The results are given below in the form of a table and in Figure 6 as dissolution profile. In Figure 11 is shown the lag-times obtained for tablets prepared according to Examples 1- 8.
  • Tablets were prepared as in Example 1 using an outer layer composi ⁇ tion as follows:
  • Lactose was sieved (300 ⁇ m mesh screen) and then premixed with Methocel® E 15 Premium. The mixture was then sieved (300 ⁇ m mesh screen) and finally mixed. Coating-by-compression
  • Tablets were manufactured as described in Example 2 by applying a compression pressure of approximately 12-14 kN.
  • the tablets manufactured as described had an average height of approximately 4.7 mm.
  • Example 5 The tablets prepared in Example 5 were tested and analyzed as described under "Method of Analysis", I.e. for all tablets dissolution testing was carried out in acidic as well as neutral dissolution media. The results are given below in the form of a table and in Figure 7 as dissolution profile. In Figure 11 is shown the lag-times obtained for tablets prepared according to Examples 1- 8.
  • Example 6 The tablets prepared in Example 6 were tested and analyzed as described under "Method of Analysis", i.e. for all tablets dissolution testing was carried out in acidic as well as neutral dissolution media. The results are given below in the form of a table and in Figure 8 as dissolution profile. In Figure 11 is shown the lag-times obtained for tablets prepared according to Examples 1-8. 80 tablets were produced as described in Example 6. The results of the dissolution testing of 6 of the tablets prepared appear below as Table 6 and the dissolution profile based on the stated mean data appears from Figure 8.
  • Tablets were prepared as described in Example 1 using a first and a second outer layer composition as follows:
  • Methocel® E 15 Premium was sieved (300 ⁇ m mesh screen) .
  • Methocel® E 50 was sieved (300 ⁇ m mesh screen) .
  • Tablets were manufactured in a double compression as described below.
  • Methocel® E 15 Premium outer layer material 50 mg Methocel® E 15 Premium outer layer material was pre-charged in a die with a punch diameter of 10.0 mm.
  • the core was placed centrally in the die by means of a centering tube. Having centered the core in the die, the die was filled with the remaining amount of the outer layer granulate, 85 mg, and a circular, plane tablet was produced by compression in a single punch tabletting machine (Diaf TM-20) applying medium pressure.
  • the tablets produced according to the above description had a height of approximately 4.5 mm.
  • Methocel® E 50 100 mg Methocel® E 50 was pre-charged in a die with a punch diameter of 12.0 mm. Having placed the double-compressed unit, consisting of core and first layer (7A) , centrally in the die, the die was filled with the remaining amount of the outer layer granulate, 150 mg, and a circular, plane tablet was produced by compression in a single punch tabletting machine (Diaf TM-20) . The tablets produced according to the above description had a height of approximately 4.8 mm.
  • Example 7 The tablets prepared in Example 7 were tested and analyzed as described under "Method of Analysis", i.e. for all tablets dissolution testing was carried out in acidic as well as neutral dissolution media. The results are given below in the form of a table and in Figure 9 as dissolution profile. In Figure 11 is shown the lag-times obtained for tablets prepared according to Examples 1-8.
  • Tablets were prepared as described in Example 7 using a first and a second outer layer composition as follows:
  • Methocel® E 50 was sieved (300 ⁇ m mesh screen) .
  • 59 mg outer layer material was pre-charged in a die with a punch diameter of 10.0 mm.
  • the core was placed centrally in the die by means of a centering tube. Having centered the core in the die, the die was filled with the remaining amount of the outer layer granulate, 100 mg, and a circular, plane tablet was produced applying medium pressure.
  • the tablets produced according to the above description had a height of approximately 4.6 mm.
  • the tablets produced according to the above description had a height of approximately 4.8 mm.
  • Example 8 The tablets prepared in Example 8 were tested and analyzed as described under "Method of Analysis", i.e. for all tablets dissolution testing was carried out in acidic as well as neutral dissolution media. The results are given below in the form of a table and in Figure 10 as dissolution profile. In Figure 11 is shown the lag-times obtained for tablets prepared according to Examples 1-8.
  • An aim of the present invention has been to develop a pharmaceutical formulation in the form of a coated solid ingestible material, preferably in the form of a unit dosage form.
  • the formulation should be substantially capable of retaining an active substance, observing four major objectives:
  • Examples 1-5 using the hydroxypropylmethylcellulose derivative Methocel® E 15 as the basis polymer (Example 1: 100% Methocel® E 15; Examples 2 and 3A+B containing 15% and 25% Macrogol 6000, respectively; and Examples 4 and 5 containing 25% Avicel® and lactose, respectively), convincingly show that tablets according to the invention with a comparatively short lag-time have been successfully manufactured. Lag-times are from 117.1 to 182.7 min. All of the tablets are capable of retaining the active substance for the greater part of the lag phase. Not until the end of the lag phase, immediately before the beginning of the burst-period, can incipient release be observed as the beginning of the subsequent burst-period.
  • the lag-time is to a remarkable extent independent of pH as shown when testing one half of the tablets from each Example in a medium of pH 1.2 and the other half in water.
  • Example 1 On the basis of the composition selected, in combination with a careful and accurate manufacturing method, unique reproducibility of the lag-time has been achieved. This can be seen from the results of Example 1 in which the same composition containing 100% Methocel® E 15 was manufactured and tested In two consecutive series of trials. 6 tablets were produced as described in Example 1 in a first experiment A, and 12 tablets were produced as described in Example 1 in a second experiment B. The data show mean lag-time of 111.7 min.
  • Example 3A a total of 80 tablets was manufactured for in vivo-study purposes (Example 9) . 5 of these tablets were tested, and subse ⁇ quently another batch of 12 tablets was prepared and tested in Example 3B.
  • the data show mean lag-time of 133.4 min. (standard deviation 24.7 minutes) in Example 3A, and 120.5 minutes (standard deviation 33.9 minutes) in Example 3B.
  • Example 6-8 the hydroxypropylmethylcellulose derivative Methocel® E 50 has been used as the basis polymer.
  • the tablets prepared in Example 6 contain 100% Methocel® E 50, whereas the tablets prepared in Example 7 contain a double-coating system in which 100% Methocel® E 15 was compression coated in the first coating and 100% Methocel® E 50 in the second coating.
  • the tablets prepared in Example 8 contain a double-coating system in which 85% Methocel® E 15 and 15% Macrogol 6000 added was compression coated in the first coating and 100% Methocel® E 50 was used for the second coating.
  • Examples 6-8 convincingly show that tablets according to the invention having a significantly longer lag-time than the short lag- time achieved with Methocel® E 15 as the basis polymer have been successfully manufactured.
  • the lag-times obtained are very long, from 317.2 minutes to 365.0 minutes. All the tablets are capable of retaining the active substance for the greater part of the lag phase as almost no active substance is dissolved. Not until the end of the lag phase, immediately before the beginning of the burst-period, can incipient release be observed as the beginning of the subsequent burst-period.
  • Example 8 (combined with Macrogol 6000 if desired) ensuring a more complete retention of the active substance before the start of the burst- period.
  • a marked reduction has been observed in the dissolved start of burst % from 22.1% (standard deviation 8.2%) in Example 6 to 11.8% (standard deviation 6.3%) in Example 7, and 11.2% (standard deviation 3.8%) in Example 8.
  • the lag-time is to a remarkable extent independent of pH as shown when testing one half of the tablets from each Example in a medium of pH 1.2 and the other half in water.
  • the dissolution of the active substance has not been negatively effected by the outer layer providing the lag-time.
  • the tablets prepared and analyzed in the in vitro Examples 1-8 demonstrate that it is possible to achieve short lag-times from approximately 2 hours up to approximately 6 hours. Lag-times between 2 and 6 hours are expected to be obtained by qualitative adjustments of the composition (e.g. mixing of the basis polymers Methocel® E 15 and Methocel® E 50) as well as quantitative adjustments.
  • a pharmaceutical formulation according to the invention has a remarkable capability of retaining the active substance completely during the lag-time, ensuring that the lag-time is substantially independent of pH, ensuring a high degree of reproducibility of the lag-time, and in those cases where a core containing an inherently substantially freely releasable active substance is used a rapid, instant release of the active substance takes place when the the lag-time has ended.
  • a pharmceutical formulation according to the invention has successfully fulfilled the objectives defined.
  • the aim of this study was to investigate the bioavailability of the two pharmaceutical formulations of the invention compared to conventional Salbutamol® 4 mg tablets.using the area under the plasma concentration-time curves (AUC) , the maximum plasma concentration (C ma ⁇ ) and the lag-time ⁇ ag as test variables.
  • the lag-time ⁇ a chorus is defined as the time period between the ingestion of the drug and the time, at which a detectable plasma concentration was measured for the first time.
  • the study was an open, controlled, randomized, balanced cross-over study with three study periods.
  • Each volunteer received one tablet (4 mg) of each formulation with a one week interval together with 150 ml water.
  • the study drugs were:
  • the volunteers had a light breakfast 11/2 hour before tablet ingestion, lunch 4 hours, and dinner 10 hous af er ingestion. Liquid consumption was controlled in the first 4 hours.
  • the purpose of the study was to Investigate the bioavailability of two tablets according to the invention, one tablet having a short lag-time and the other tablet having a lag-time which is long compared with the gastrointestinal transit time of a pharmaceutical formulation according to the invention.
  • the in vivo study has con ⁇ firmed the capability of the pharmaceutical formulation according to the Invention to give the desired unique release.
  • Formulation A (the tablet prepared as described in Example 3A) showed a significant lag- time when compared to the uncoated core which was used as a reference formulation C in the study (see Tables 9F and 9G as well as Figure 12).
  • Formulation B showed a longer lag-time than formulation A in all subjects, and the lag-time ⁇ ac , appeared to be considerably longer than the lag-time determined in vitro , so the prototype formulation chosen for the in vivo study bursted at a time (median 7.5 hours) when the formulation, according to general knowledge about transit times, is expected to be in the colon, i.e. at a site where the absorption capacity for salbutamol and,not the release from the formulations Is the limiting factor for absorption.
  • Methocel® K 100 was sieved (300 ⁇ m mesh screen) .
  • Example 10 The tablets prepared in Example 10 were tested and analyzed as described under "Method of Analysis", i.e. for all tablets dissolution testing was carried out in acidic as well as neutral dissolution media. The results are given below in the form of a table.
  • Methocel® K 100 was sieved (300 ⁇ m mesh screen) .
  • Example 11 The tablets prepared in Example 11 were tested and analyzed as described under "Method of Analysis", i.e. for all tablets dissolution testing was carried out in acidic as well as neutral dissolution media. The results are given below in the form of a table.
  • Tablets were prepared as described in Example 7 using a first and a second outer layer composition as follows:
  • Methocel® E 15 was sieved (300 ⁇ m mesh screen) .
  • Methocel® K 100 was sieved (300 ⁇ m mesh screen) Coating by compression
  • Tablets were manufactured in double compression as described below.
  • Example 12 The tablets prepared in Example 12 were tested and analyzed as described under "Method of Analysis", i.e. for all tablets dissolution testing was carried out in acidic as well as neutral dissolution media. The results are given below in the form of a table and in Figures 14 as dissolution profile. In Figure 11 is also shown the lag-times obtained for tablets prepared according to Example 12.
  • Second coating 100% Methocel® K 100 6 tablets were produced as described in Example 12. The results of the dissolution testing of the tablets prepared appear below as Table 12 and the dissolution profile based on the stated mean data appears from Figure 14.
  • a tablet consisting of the following ingredients was used as core in this example:
  • the dissolution profile of the core was determined by dissolution testing in purified water at 37 C C and in 0.1 N hydrochloric acid at 37°C in accordance with Ph. Eur. V.5.4. (1991 edition), using a dissolution apparatus equipped with baskets rotating at 100 rpm. Determined as mean data, the core releases at least 90% by weight of the total content of caffeine during a period of at the most 45 minutes.
  • Tablettose, Ac-Di-Sol, Avicel® PH 101, and caffeine were sieved (300 ⁇ m mesh screen) and mixed.
  • Magnesium stearate + talc (1:9) were sieved (300 ⁇ m mesh screen) and mixed with the rest of core composi ⁇ tion 13.
  • Circular, plane tablets were produced by compression in a single punch tabletting machine (Diaf TM 20) .
  • the tablets produced according to the above description had an average height of approximately 4.0 mm and an average weight of approximately 246 mg.
  • 150 mg outer layer granulate was pre-charged in a die with a punch diameter of 11.0 mm.
  • the core was placed centrally in the die by means of a centering tube. Having centered the core in the die, the die was filled with the remaining amount of the outer layer granulate (180 mg) and a circular, plane tablet was produced by compression in special compression equipment (Fette Exacta 1/F, instrumentated tabletting machine) applying a pressure of about 13 kN.
  • the tablets produced according to the above description had an average height of approximately 4.7 mm.
  • Example 13 The tablets prepared in Example 13 were tested and analyzed as described under "Method of Analysis", i.e. for all tablets dissolution testing was carried out in acidic as well as neutral dissolution media. The results are given below in the form of a table and in Figure 15 as dissolution profile. In Figure 11 is also shown the lag-times obtained for tablets prepared according to Example 13.
  • Example 10 the hydroxypropylmethylcellulose derivative Methocel® K 100 has been used as the basis polymer.
  • the tablets prepared in Example 10 contain 297 mg Methocel® K 100, whereas the tablets prepared in Example 11 contain 238 mg Methocel® K 100.
  • a considerably longer lag-time was found (mean lag-time 485.2 minutes versus 317.2 minutes), and the burst-period was also considerably prolonged (mean burst-period 70.4 minutes versus 21.2 minutes) .
  • Example 12 100% Methocel® E 15 was used in a first coating and 100% Methocel® K 100 in a second coating.
  • the lag-time obtained was not considerably prolonged when compared to the lag-time obtained in Example 11 (mean lag-time 363.9 minutes versus 381.8 minutes).
  • the burst-period obtained in Example 12 was, however, considerably shor ⁇ ter than the burst-period obtained in Example 11 (mean burst-period 13.9 minutes versus 31.1 minutes).
  • the effect of the double-coating when compared with the results obtained in Example 11 was thus, that a lag-time of about the same length could be obtained and at the same time a considerably shorter burst-period.
  • Tablets were prepared consisting exclusively of the outer layer, i.e. no core was used.
  • the outer layer composition was as follows:
  • Methocel E® 15 was sieved (300 ⁇ m mesh screen) .
  • Methocel® E 50 was sieved (300 ⁇ m mesh screen) .
  • Tablets were prepared consisting exclusively of the outer layer, i.e. no core was used.
  • the outer layer composition was as follows:
  • Methocel® K 100 was sieved (300 ⁇ m mesh screen).
  • the tablets prepared In Examples 14-16 were tested and analyzed as described under "Method of Analysis", i.e. for all tablets dissolution testing was carried out in acidic as well as neutral dissolution media. The concentration of the hydroxypropylmethyl ⁇ cellulose in question in the dissolution medium was measured until no further increase of the concentration was observed. The concentration of the hydroxypropylmethylcellulose was found to increase liniarly by time. The results are given below in the form of Table 14.
  • Methocel® E 15 Approximately 0.8
  • Example l The tablets prepared in Example lwere tested and analyzed as described under "Method of Analysis", i.e. for all tablets dissolution testing was carried out in acidic as well as neutral dissolution media. The results are given below in the form of a table. 6 tablets were produced as described In Example 17. The results of the dissolution testing of the 6 tablets prepared appear below as Table 15.
  • Example 13 The tablets prepared in Example 13 were tested and analyzed as described under "Method of Analysis", i.e. for all tablets dissolution testing was carried out in acidic as well as neutral dissolution media. The results are given below in the form of a table.
  • Methocel® E 4M alone in a coating does not seem to be a preferred material in this invention.
  • a tablet consisting of the following ingredients was used as core in this example.
  • the dissolution profile of the core was determined by dissolution testing in purified water at 37°C and in 0.1 N hydrochloric acid at 37°C in accordance with Ph. Eur. V.5.4. (1991 edition), using a dissolution apparatus equipped with baskets rotating at 100 rpm. Determined as mean data, the core releases at least 90% by weight of the total content of caffeine during a period of at the most 45 minutes.
  • Tabletose®, Avicel® PH 101 and caffeine were sieved (300 ⁇ m mesh screen) and mixed.
  • Magnesium stearate + talc (1:9) were sieved
  • Circular, plane tablets were produced by compression in a single punch tabletting machine (Diaf TM 20) .
  • the tablets produced according to the above description had an average weight of approximately 103 mg and a diameter of 6 mm.
  • Klucel® MF, Klucel® LF and lactose were mixed and subsequently granulated with water. After drying and sieving (300 ⁇ m mesh screen) magnesium stearate was admixed.
  • 100 mg outer layer granulate was pre-charged in a die with a punch diameter of 10.0 mm.
  • the core was placed centrally in the die. Having centered the core in the die, the die was filled with the remaining amount of the outer layer granulate (100 mg) , and a circular, plane tablet was produced by compression in a single punch tabletting machine (Diaf TM 20) .
  • Example 19 The tablets prepared in Example 19 were tested and analyzed as described under "Method of Analysis", i.e. for all tablets dissolution testing was carried out in acidic as well as neutral dissolution media. The results are given below in the form of a table and in Figure 16 as dissolution profile.
  • Example 19 A core as described in Example 19, i.e. core composition 19, was used, and tablets were prepared as described in Example 19, using the outer layer composition 19.
  • 150 mg outer layer granulate was pre-charged in a die with a punch diameter of 10.0 mm.
  • the core was placed centrally in the die. Having centered the core in the die, the die was filled with the remaining amount of the outer layer granulate (150 mg) , and a circular, plane tablet was produced by compression in a single punch tabletting machine (Diaf TM 20) .
  • Example 20 The tablets prepared in Example 20 were tested and analyzed as described under "Method of Analysis", i.e. for all tablets dissolution testing was carried out in acidic as well as neutral dissolution media. The results are given below in the form of a table and in Figure 17 as dissolution profile.
  • Core composition 21 A tablet consisting of the following ingredients was used as core in this example.
  • Core composition 21 A tablet consisting of the following ingredients was used as core in this example.
  • the dissolution profile of the core was determined by dissolution testing in purified water at 37°C and in 0.1 N hydrochloric acid at 37°C in accordance with Ph. Eur. V.5.4. (1991 edition), using a dissolution apparatus equipped with baskets rotating at 100 rpm. Determined as mean data, the core releases at least 90% by weight of the total content of caffeine during a period of at the most 45 minutes.
  • Tabletose®, Avicel® PH 101 and caffeine were sieved (300 ⁇ m mesh screen) and mixed.
  • Magnesium stearate + talc (1:9) were sieved (300 ⁇ m mesh screen) and mixed with the rest of core composition 21.
  • Circular, plane tablets were produced by compression in a single punch tabletting machine (Diaf TM 20) .
  • the tablets produced according to the above description had an average weight of approximately 370 mg and a diameter of 10 mm.
  • Magnesium stearate 0.6 Klucel® MF, Klucel® LF and lactose were mixed and subsequently granulated with water. After drying and sieving (300 ⁇ mesh screen) magnesium stearate was admixed.
  • 200 mg outer layer granulate was pre-charged in a die with a punch diameter of 12.0 mm.
  • the core was placed centrally in the die. Having centered the core in the die, the die was filled with the remaining amount of the outer layer granulate (200 mg) , and a circular, plane tablet was produced by compression in a single punch tabletting machine (Diaf TM 20) .
  • Example 21 The tablets prepared in Example 21 were tested and analyzed as described under "Method of Analysis", i.e. for all tablets dissolution testing was carried out in acidic as well as neutral dissolution media. The results are given below in the form of a table and in Figure 18 as dissolution profile.
  • Examples 19-21 using the hydroxypropylcellulose derivatives Klucel® MF and Klucel® LF as the basic polymers in the outer layer convincingly show that on this basis tablets do not have a satisfactorily short burst-period after the end of the lag-time. Variation in the amount of material used in the outer layer does not remedy this problem. Thus a lag-time of 125 minutes resulted in a burst-period of 321 minutes, and a lag-time of 291 minutes resulted in a burst-period of 525 minutes (Examples 19 and 20) . A change of the diameter of the core and the finished tablet did not result in satisfactory time intervals for the burst-period either. Thus a lag- time of 451 minutes resulted in a burst-period of 219 minutes (Example 21) .
  • the amount of active substance released during the burst-period is not satisfactory when a core diameter of 10 mm and a diameter of the finished tablet of 12 mm are used. A value of 59.4% was achieved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulation pharmaceutique permettant la libération régulée d'une substance active, et comportant une matière ingérable solide et administrable par voie orale contenant de préférence une substance officinale active ainsi qu'une ou plusieurs couches dépérissables entourant et recouvrant la matière ingérable solide. Au moins une des couches dépérissables contient, à titre d'ingrédient principal, un ou plusieurs dérivés cellulosiques hydrosolubles, par exemple l'hydroxypropylméthylcellulose, l'hydroxypropylcellulose, ou la méthylcellulose, dont la viscosité est telle qu'une composition de contrôle comportant une combinaison (C) (1) d'un noyau contenant une substance active sous forme sensiblement libre de manière inhérente, et (2) d'une ou plusieurs couches dépérissables, peut libérer, après un délai (A) prédéterminé d'au moins 60 minutes pendant lesquelles 30 % en poids au maximum de ladite substance active est libérée, au moins 70 % en poids de ladite substance active contenue dans le noyau, et cela pendant une période de libération accélérée dont la durée est de 45 minutes au maximum, lesdites libérations étant mesurées sous forme de données moyennes déterminées par un contrôle de dissolution effectué dans de l'eau purifiée à 37° et dans de l'acide 0,1 N-chlorhydrique à 37°, conformément à Ph.Eur. V.5.4. (édition de 1991), à l'aide d'un appareil de dissolution équipé de bols tournant à 100 tours/min.
PCT/DK1993/000117 1992-03-31 1993-03-30 Formulation pharmaceutique WO1993019741A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPCT/DK92/00101 1992-03-31
DK9200101 1992-03-31

Publications (1)

Publication Number Publication Date
WO1993019741A1 true WO1993019741A1 (fr) 1993-10-14

Family

ID=8153847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1993/000117 WO1993019741A1 (fr) 1992-03-31 1993-03-30 Formulation pharmaceutique

Country Status (2)

Country Link
AU (1) AU3949093A (fr)
WO (1) WO1993019741A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013029A1 (fr) * 1996-09-23 1998-04-02 Duphar International Research B.V. Formulation retard a administration par voie orale et procede de preparation de cette formulation
WO2004047794A3 (fr) * 2002-11-26 2004-09-16 Alk Abello As Forme doseifiee d'un allergene
WO2004093843A1 (fr) * 2003-04-24 2004-11-04 Jagotec Ag Comprime a action retardee et a geometrie de noyau definie
EP2120888A1 (fr) * 2007-03-15 2009-11-25 Polichem SA Formes de dosage à libération retardée/pulsatile en fonction du temps
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
WO2012158030A3 (fr) * 2011-05-13 2013-04-18 Emotional Brain B.V. Système d'administration de médicament
US8920838B2 (en) 2006-08-03 2014-12-30 Horizon Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
WO2016075495A1 (fr) * 2014-11-14 2016-05-19 Drug Delivery International Ltd Composition

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB793808A (en) * 1954-07-22 1958-04-23 Frank Mario Bardani Sustained action pill
FR2276108A1 (fr) * 1974-06-24 1976-01-23 Shinetsu Chemical Co Procede de revetement de certaines formes de presentation de doses de produits
EP0013131A2 (fr) * 1978-12-27 1980-07-09 Mundipharma A.G. Composition pharmaceutique sous forme de dosage solide et procédé pour sa fabrication
DE3013059A1 (de) * 1980-04-03 1981-10-08 Sandoz-Patent-GmbH, 7850 Lörrach Neue galenische zusammensetzung
EP0210540A1 (fr) * 1985-07-19 1987-02-04 Fujisawa Pharmaceutical Co., Ltd. Systèmes d'explosion à retardement et procédé pour leur préparation
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
EP0299211A1 (fr) * 1987-06-24 1989-01-18 Bayer Ag Comprimé enrobé en DHP
GB2212396A (en) * 1987-12-18 1989-07-26 Procter & Gamble Dietary supplement comprising calcium and delayed release coated iron
EP0384514A2 (fr) * 1989-02-21 1990-08-29 Norwich Eaton Pharmaceuticals, Inc. Comprimé à double effet
EP0411590A2 (fr) * 1989-08-02 1991-02-06 ARNOLD, John David Procédé et préparation pour diminuer le risque d'un infarctus du myocarde
GB2245492A (en) * 1990-07-04 1992-01-08 Zambon Spa Programmed release oral solid pharmaceutical dosage form

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB793808A (en) * 1954-07-22 1958-04-23 Frank Mario Bardani Sustained action pill
FR2276108A1 (fr) * 1974-06-24 1976-01-23 Shinetsu Chemical Co Procede de revetement de certaines formes de presentation de doses de produits
EP0013131A2 (fr) * 1978-12-27 1980-07-09 Mundipharma A.G. Composition pharmaceutique sous forme de dosage solide et procédé pour sa fabrication
DE3013059A1 (de) * 1980-04-03 1981-10-08 Sandoz-Patent-GmbH, 7850 Lörrach Neue galenische zusammensetzung
EP0210540A1 (fr) * 1985-07-19 1987-02-04 Fujisawa Pharmaceutical Co., Ltd. Systèmes d'explosion à retardement et procédé pour leur préparation
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
EP0299211A1 (fr) * 1987-06-24 1989-01-18 Bayer Ag Comprimé enrobé en DHP
GB2212396A (en) * 1987-12-18 1989-07-26 Procter & Gamble Dietary supplement comprising calcium and delayed release coated iron
EP0384514A2 (fr) * 1989-02-21 1990-08-29 Norwich Eaton Pharmaceuticals, Inc. Comprimé à double effet
EP0411590A2 (fr) * 1989-08-02 1991-02-06 ARNOLD, John David Procédé et préparation pour diminuer le risque d'un infarctus du myocarde
GB2245492A (en) * 1990-07-04 1992-01-08 Zambon Spa Programmed release oral solid pharmaceutical dosage form

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PHARM. IND. vol. 41, no. 8, 1979, pages 799 - 802 SALOMON J.L. ET AL 'sustained release of a water soluble drug from hydrophilic compressed dosage form' cited in the application *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013029A1 (fr) * 1996-09-23 1998-04-02 Duphar International Research B.V. Formulation retard a administration par voie orale et procede de preparation de cette formulation
US6183780B1 (en) 1996-09-23 2001-02-06 Duphar International Research B.V. Oral delayed immediate release formulation and method for preparing the same
WO2004047794A3 (fr) * 2002-11-26 2004-09-16 Alk Abello As Forme doseifiee d'un allergene
US10471008B2 (en) 2002-11-26 2019-11-12 Alk-Abelló A/S Allergen dosage form
US10080719B2 (en) 2002-11-26 2018-09-25 Alk-Abelló A/S Allergen dosage form
US9415015B2 (en) 2002-11-26 2016-08-16 Alk-Abello A/S Allergen dosage form
US9408805B2 (en) 2002-11-26 2016-08-09 Alk-Abello A/S Allergen dosage form
US8329196B2 (en) 2002-11-26 2012-12-11 Alk-Abello A/S Allergen dosage form
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
US9040085B2 (en) 2003-04-24 2015-05-26 Jagotec Ag Delayed release tablet with defined core geometry
US8168218B2 (en) 2003-04-24 2012-05-01 Jagotec Ag Delayed release tablet with defined core geometry
WO2004093843A1 (fr) * 2003-04-24 2004-11-04 Jagotec Ag Comprime a action retardee et a geometrie de noyau definie
US8394407B2 (en) 2003-04-24 2013-03-12 Jagotec Ag Delayed release tablet with defined core geometry
US9186332B2 (en) 2003-04-24 2015-11-17 Jagotec Ag Delayed release tablet with defined core geometry
US9884021B2 (en) 2003-04-24 2018-02-06 Jagotec Ag Delayed release tablet with defined core geometry
US8309124B2 (en) 2003-04-24 2012-11-13 Jagotec Ag Delayed release tablet with defined core geometry
US9504699B2 (en) 2006-08-03 2016-11-29 Hznp Limited Delayed-release glucocorticoid treatment of rheumatoid disease
US8920838B2 (en) 2006-08-03 2014-12-30 Horizon Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
EP2120888A1 (fr) * 2007-03-15 2009-11-25 Polichem SA Formes de dosage à libération retardée/pulsatile en fonction du temps
WO2012158030A3 (fr) * 2011-05-13 2013-04-18 Emotional Brain B.V. Système d'administration de médicament
US9763884B2 (en) 2011-05-13 2017-09-19 Eb Ip Hybritabs B.V. Drug delivery system
EA034288B1 (ru) * 2011-05-13 2020-01-24 Эб Ип Хибритабс Б.В. Система доставки лекарственного средства
US10966933B2 (en) 2011-05-13 2021-04-06 Eb Ip Hybritabs B.V. Drug delivery system
WO2016075495A1 (fr) * 2014-11-14 2016-05-19 Drug Delivery International Ltd Composition
US10675247B2 (en) 2014-11-14 2020-06-09 Drug Delivery International Ltd. Press coated tablet prepared for delayed release of an active ingredient

Also Published As

Publication number Publication date
AU3949093A (en) 1993-11-08

Similar Documents

Publication Publication Date Title
EP0954292B1 (fr) Formulations pharmaceutiques a liberation retardee
US5316772A (en) Bilayered oral pharmaceutical composition with pH dependent release
US5891474A (en) Time-specific controlled release dosage formulations and method of preparing same
JP4012689B2 (ja) 新規徐放性経口製剤
AU736052B2 (en) Pharmaceutical compositions for controlled release of active substances
US7674480B2 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6703044B1 (en) Venlafaxine formulations
US6476006B2 (en) Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
CN102387802B (zh) 包含羟考酮和纳洛酮的立即释放药物组合物
US6899896B2 (en) Hydrogel-driven layered drug dosage form
US10441585B2 (en) Formulations containing nalbuphine and uses thereof
HUP0301465A2 (hu) Gyorsan duzzadó készítmény gyomori retencióra és terápiás hatóanyagok szabályozott kioldódására, és a készítményt tartalmazó adagolási formák
JPH09183728A (ja) 固体薬剤調製物
JPH061716A (ja) 活性成分の長期放出性を有する投薬形
RU2377976C2 (ru) ФАРМАЦЕВТИЧЕСКАЯ МНОГОСЛОЙНАЯ ТАБЛЕТКА ДЛЯ КОНТРОЛИРУЕМОГО ВЫСВОБОЖДЕНИЯ АКТИВНЫХ ИНГРЕДИЕНТОВ С РАСТВОРИМОСТЬЮ, В ВЫСОКОЙ СТЕПЕНИ ЗАВИСЯЩЕЙ ОТ pH
PL211301B1 (pl) Tabletka wielowarstwowa dyspergowalna w ustach oraz sposób jej wytwarzania
WO1998027967A1 (fr) Comprimes enrobes a liberation controlee
EP1814529B1 (fr) Forme posologique pour medicament à temps de latence contre l'insomnie
WO1993019741A1 (fr) Formulation pharmaceutique
KR20070036797A (ko) 장용 코팅된 중심정을 갖는 제형
CN115297848B (zh) 一种非布司他片
EP0700285A1 (fr) Composition medicamenteuse a base d'agent bloquant du recepteur alpha-adrenergique s'administrant oralement
JPH07126153A (ja) 大腸内放出型医薬製剤用粒状物
KR20230152051A (ko) 멜라토닌을 포함하는 다층 펠릿의 제형(formulation of a multilayered pellet comprising melatonin)
WO2004037226A2 (fr) Compositions pharmaceutiques renfermant de la venlafaxine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BG BR CA CZ FI HU JP KR KZ NO NZ PL RO RU SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA